Supriya Lifescience Limited (IN:SUPRIYA)
:SUPRIYA
Want to see IN:SUPRIYA full AI Analyst Report?
SUPRIYA Stock Chart & Stats
₹751.00
-₹18.10(-2.41%)
At close: 4:00 PM EST
₹751.00
-₹18.10(-2.41%)
Day’s Range― - ―
52-Week Range₹545.65 - ₹1,085.50
Previous CloseN/A
Volume168.68K
Average Volume (3M)18.01K
Market Cap
₹76.66B
Enterprise Value₹77.23B
Total Cash (Recent Filing)₹1.06B
Total Debt (Recent Filing)₹52.32M
Price to Earnings (P/E)36.7
Beta1.24
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)22.67
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.5
Revenue Forecast (FY)₹9.94B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low leverage and a growing equity base provide durable financial flexibility. This reduces bankruptcy and refinancing risk, supports investment or M&A without heavy external funding, and helps the company withstand cyclical pharma demand or regulatory-driven delays over the next 2–6 months.
Improving Operating Cash Flow And Internal FundingA sustained improvement in operating cash flow increases earnings quality and funds growth or capex internally. Strong 2025–2026 cash generation reduces near-term reliance on external capital, supports working-capital needs, and underpins durable operational resilience over coming months.
Strong Recent Revenue Growth And API Market ExposureConsistent, double-digit revenue growth and a broad API product set serving domestic and export markets indicate solid market demand and diversified customer end-markets. This supports sustainable top-line momentum and scale economies for manufacturing over the medium term.
Bears Say
Margin And Earnings VolatilityHistorical swings in margins and earnings reduce predictability of profitability and make forward cashflow estimates less reliable. For a manufacturing-focused API business, variability from product mix, pricing, or cost inputs can persist and affect stakeholder planning over the next several quarters.
Inconsistent Free Cash Flow HistoricallyPeriods of negative free cash flow reflect heavy investment or working-capital swings, which can limit ability to fund dividends, buybacks, or opportunistic investments during downturns. Past volatility suggests cash generation may revert if investment or working-capital needs recur.
Moderating Returns And Concentration On API ManufacturingWhile ROE remains positive, moderation from prior peaks signals potential margin pressure or slower leverage of assets. Combined with a business model dependent on API manufacturing, this implies sensitivity to pricing, regulatory quality demands, and customer concentration that could cap returns over the medium term.
Supriya Lifescience Limited News
SUPRIYA FAQ
What was Supriya Lifescience Limited’s price range in the past 12 months?
Supriya Lifescience Limited lowest stock price was ₹545.65 and its highest was ₹1085.50 in the past 12 months.
What is Supriya Lifescience Limited’s market cap?
Supriya Lifescience Limited’s market cap is ₹76.66B.
When is Supriya Lifescience Limited’s upcoming earnings report date?
Supriya Lifescience Limited’s upcoming earnings report date is Aug 10, 2026 which is in 60 days.
How were Supriya Lifescience Limited’s earnings last quarter?
Supriya Lifescience Limited released its earnings results on May 27, 2026. The company reported ₹9.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹9.2.
Is Supriya Lifescience Limited overvalued?
According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued.
Does Supriya Lifescience Limited pay dividends?
Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here
What is Supriya Lifescience Limited’s EPS estimate?
Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Supriya Lifescience Limited have?
Supriya Lifescience Limited has 80,482,800 shares outstanding.
What happened to Supriya Lifescience Limited’s price movement after its last earnings report?
Supriya Lifescience Limited reported an EPS of ₹9.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.5%.
Which hedge fund is a major shareholder of Supriya Lifescience Limited?
Currently, no hedge funds are holding shares in IN:SUPRIYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Supriya Lifescience Limited
Supriya Lifescience Ltd. is an Indian pharmaceutical enterprise, established in 1987 and headquartered in Mumbai. The company's primary business involves the global research, development, manufacturing, and commercialization of Active Pharmaceutical Ingredients (APIs), positioning it as a significant producer of bulk drug components. Its extensive range of APIs caters to diverse therapeutic areas, including anti-histamines, anti-allergics, anti-asthmatics, decongestants, analgesics, antipyretics, anesthetics, smoking cessation aids, anti-hypertensives, and anti-malarials. Additionally, Supriya Lifescience also supplies various other products, such as vitamins, animal feed additives, xanthine derivatives (some of which are used in beverages), and phytochemicals.
Technical Analysis
Blue Jet Healthcare Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Zota Health Care Ltd.
―
OneSource Specialty Pharma Limited
―